Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

• Published in: Acta pharmaceutica Sinica. B Vol. 10; no. 5; pp. 766 - 788
• Main Authors: Wu, Canrong, Liu, Yang, Yang, Yueying, Zhang, Peng, Zhong, Wu, Wang, Yali, Wang, Qiqi, Xu, Yang, Li, Mingxue, Li, Xingzhou, Zheng, Mengzhu, Chen, Lixia, Li, Hua
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.05.2020; Elsevier
• Subjects: Drug repurposing; Homology modeling; Molecular docking; Original article; Remdesivir; SARS-CoV-2; ORF; SUD; E; Drug repurposing; 3CLpro; Nsp; M; UB; Molecular docking; N; PDB; SARS-CoV-2; S; RdRp; Homology modeling; Remdesivir; N, nucleocapsid protein; ORF, open reading frame; M, membrane protein; S, Spike; 3CLpro, 3-chymotrypsin-like protease; UB, ubiquitin-like domain; RdRp, RNA-Dependence RNA polymerase; Nsp, non-structure protein; PDB, protein data bank; E, envelope; SUD, SARS unique domain

SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden i...